Timber Creek Capital Management’s AstraZeneca AZN Stock Holding History

Timber Creek Capital Management’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$6.15M	Buy	+32,445	New	+$6.1M	1.26%	25
2026 Q1	–	Sell	-30,708	Closed	-$5.65M	–	80
2025 Q4	$5.65M	Sell	30,708 -230	-0.7%	-$40.3K	1.31%	29
2025 Q3	$4.75M	Sell	30,938 -144	-0.5%	-$21.8K	1.15%	33
2025 Q2	$4.63M	Sell	31,082 -29	-0.1%	-$4.06K	1.18%	32
2025 Q1	$4.57M	Sell	31,111 -27	-0.1%	-$3.91K	1.22%	34
2024 Q4	$4.08M	Sell	31,138 -476	-2%	-$66.6K	1.18%	34
2024 Q3	$4.93M	Buy	31,614 +227	+0.7%	+$36.6K	1.38%	29
2024 Q2	$4.9M	Sell	31,387 -5,967	-16%	-$898K	1.48%	27
2024 Q1	$5.06M	Sell	37,354 -3,005	-7%	-$398K	1.58%	23
2023 Q4	$5.44M	Buy	40,359 +518	+1%	+$67.3K	1.85%	18
2023 Q3	$5.4M	Sell	39,841 -675	-2%	-$92.2K	1.95%	18
2023 Q2	$5.8M	Sell	40,516 -27	-0.1%	-$3.97K	2%	17
2023 Q1	$5.63M	Sell	40,543 -47	-0.1%	-$6.32K	2.01%	16
2022 Q4	$5.5M	Sell	40,590 -176	-0.4%	-$22.1K	2.08%	16
2022 Q3	$4.47M	Sell	40,766 -1,688	-4%	-$214K	1.77%	24
2022 Q2	$5.61M	Sell	42,454 -8,534	-17%	-$1.12M	1.85%	20
2022 Q1	$6.76M	Buy	50,988 +5,099	+11%	+$611K	2.05%	16
2021 Q4	$5.35M	Buy	45,889 +827	+2%	+$97.3K	1.59%	28
2021 Q3	$5.41M	Buy	45,062 +159	+0.4%	+$18.5K	1.72%	29
2021 Q2	$5.38M	Buy	44,903 +6,575	+17%	+$721K	1.74%	29
2021 Q1	$3.81M	Buy	38,328 +2,583	+7%	+$260K	1.47%	30
2020 Q4	$3.57M	Buy	35,745 +372	+1%	+$39.4K	1.59%	25
2020 Q3	$3.88M	Buy	35,373 +225	+0.6%	+$25K	2.13%	17
2020 Q2	$3.72M	Buy	35,148 +1,143	+3%	+$118K	2.33%	17
2020 Q1	$3.04M	Buy	+34,005	New	+$3.2M	2.22%	16

Other funds holding AZN

Evelyn Partners London $46.9B AUM

Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Timber Creek Capital Management's AZN Position: Q2 2026 in Review

Timber Creek Capital Management opened a new position in AstraZeneca (AZN) in Q2 2026: 32,445 shares worth $6.15M. The stake represents 1.26% of the portfolio and ranks #25 among its holdings. This is a return to the name: Timber Creek Capital Management previously reported a position in AZN as recently as Q4 2025.

Timber Creek Capital Management first reported a position in AZN in Q1 2020 and has held it in 25 quarters since. The position peaked at $6.76M in Q1 2022. 1,503 funds tracked by Wall St. Rank hold AZN as of Q2 2026.

Timber Creek Capital Management held 32,445 shares of AstraZeneca worth $6.15M as of Q2 2026.
AstraZeneca was a new Timber Creek Capital Management position in Q2 2026.
AstraZeneca made up 1.26% of Timber Creek Capital Management's portfolio in Q2 2026, its #25 holding.
Timber Creek Capital Management first reported a position in AstraZeneca in Q1 2020 and has held it in 25 quarters since.
Timber Creek Capital Management's AstraZeneca position peaked at $6.76M in Q1 2022.
1,503 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.

Based on Timber Creek Capital Management's 13F filing for Q2 2026, filed 10 Aug 2026.